<DOC>
	<DOCNO>NCT01642238</DOCNO>
	<brief_summary>The purpose study determine whether treatment ticagrelor ( plus aspirin bivalirudin ) effective treatment clopidogrel ( plus aspirin bivalirudin ) .</brief_summary>
	<brief_title>Antithrombotic Effects Ticagrelor Versus Clopidogrel</brief_title>
	<detailed_description>The HORIZONS-AMI Trial compare effectiveness heparin plus glycoprotein IIb/IIIa inhibitor ( GPI ) versus bivalirudin acute myocardial infarction ( AMI ) patient undergo stent deployment 1 . Overall data show benefit associate bivalirudin treatment low rate all-cause mortality , cardiac mortality , re-infarction non-CABG related major bleeding ; However , data seem indicate non-significant increase acute stent thrombosis bivalirudin group . This observation seem suggest potential benefit add antiplatelet agent bivalirudin . A study Dangas G et al find HORIZONS-AMI patient , group receive 600 mg loading-dose clopidogrel significantly low 30-day unadjusted rate mortality , reinfarction stent thrombosis 300 mg loading-dose group , without increase bleeding rate . Furthermore , even though benefit bivalirudin independent clopidogrel load dose ; 600mg LD associate benefit anticoagulation regimen . Similar observation report ARMYDA-6 MI study . It hypothesis use ticagrelor instead clopidogrel , give potent faster activity , would great antithrombotic activity therefore may reduce rate acute stent thrombosis administer combination bivalirudin + ASA AMI patient . To investigate hypothesis , compare antithrombotic effect ticagrelor clopidogrel , administer combination ASA bivalirudin , healthy human volunteer use cross-over study design . The antithrombotic activity assess pre-treatment 2-hours 24-hours post treatment , use methodology include Badimon Perfusion chamber , VerifyNow P2Y12 assay , platelet aggregation Multiplate Analyzer Thromboelastography .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male female volunteer 18 65 year old . Body mass index ( BMI ) 18 30 kg/m2 inclusive . Healthy assess detailed medical history physical examination . Laboratory est result within normal range . Ability provide sign informed consent . History clinically relevant disease , bleeding , acute infectious disease sign acute illness . Allergy hypersensitivity aspirin thienopyridines , atopy diagnose physician . Use medication within one month prior study drug administration . History drug abuse alcohol consumption &gt; 20 g/day . Inability abstain intensive muscular effort sport competition . Loss &gt; 400 mL blood blood donation within 3 month . Positive serology hepatitis B ( HBs Ag ) hepatitis C. Conditions associate hemorrhagic risk . Positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Antiplatelet</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>bivalirudin</keyword>
	<keyword>thrombosis</keyword>
</DOC>